References
- Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsDepartment of Health and Human Services [updated February 12, 2013]. Available from: http://aidsinfo.nih.gov/contentfles/lvguidelines/adultandadolescentgl.pdfAccessed February 25, 2013
- MaltêzFDoroanaMBrancoTValenteCRecent advances in antiretroviral treatment and prevention in HIV-infected patientsCurr Opin HIV AIDS20116Suppl 1S21S3022156776
- CohenMSChenYQMcCauleyMHPTN 052 Study TeamPrevention of HIV-1 infection with early antiretroviral therapyN Engl J Med2011365649350521767103
- ThompsonMAAbergJAHoyJFAntiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panelJAMA2012308438740222820792
- HasseBLedergerberBFurrerHSwiss HIV Cohort StudyMorbidity and aging in HIV-infected persons: the Swiss HIV cohort studyClin Infect Dis201153111130113921998280
- KrentzHBCosmanILeeKMingJMGillMJPill burden in HIV infection: 20 years of experienceAntivir Ther201217583384022358155
- MarzoliniCBackDWeberRSwiss HIV Cohort Study MembersAgeing with HIV: medication use and risk for potential drug-drug interactionsJ Antimicrob Chemother20116692107211121680580
- LlibreJMArribasJRDomingoPSpanish Group for FDAC EvaluationClinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapyAIDS201125141683169021673556
- SaxPEMeyersJLMugaveroMDavisKLAdherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United StatesPLoS One201272e3159122384040
- Tibotec PharmaceuticalsEdurant™ (rilpivirine) tablets [prescribing information]Raritan, NJ2011
- GhosnJChaixMLDelaugerreCHIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitorsAIDS Rev200911316517319654858
- DeeksEDKeatingGMEtravirineDrugs200868162357237218973398
- AzijnHTirryIVingerhoetsJTMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1Antimicrob Agents Chemother201054271872719933797
- LewisWDayBJCopelandWCMitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspectiveNat Rev Drug Discov200321081282214526384
- GoebelFYakovlevAPozniakALShort-term antiviral activity of TMC278 – a novel NNRTI, in treatment-naive HIV-1-infected subjectsAIDS200620131721172616931936
- European Medicines AgencyEdurant® 25 mg Film-Coated Tablets: Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdfAccessed December 9, 2011
- Lachau-DurandSMamidiRNVSCuyckensFAbsorption, metabolism and excretion of TMC278, a next- generation non-nucleoside reverse transcriptase inhibitor (NNRTI), after a single oral dose of 150 mg in healthy male volunteers12th European AIDS ConferenceNovember 11–14, 2009Cologne, Germany Abstract no PE7.1/3
- European Medicines AgencyEviplera ™ 200 mg/25 mg/245 mg film coated tablets: Summary of product characteristics Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002312//WC500118802.pdfAccessed February 25, 2013
- Gilead Sciences, IncComplera™: US Prescribing Information Available from: www.gilead.com/medicines#hivaidsAccessed February 25, 2013
- IslamFMWuJJanssonJWilsonDPRelative risk of renal disease among people living with HIV: a systematic review and meta-analysisBMC Public Health201212123422439731
- YoungJSchäferJFuxCASwiss HIV Cohort StudyRenal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavirAIDS201226556757522398568
- ScherzerREstrellaMLiYAssociation of tenofovir exposure with kidney disease risk in HIV infectionAIDS201226786787522313955
- PozniakALMorales-RamirezJKatabiraETMC278-C204 Study GroupEfficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trialAIDS2010241556519926964
- MolinaJMCahnPGrinsztejn B, et al; ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialLancet2011378978723824621763936
- CohenCJAndrade-VillanuevaJClotetBTHRIVE study groupRilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialLancet2011378978722923721763935
- RimskyLVingerhoetsJVan EygenVGenotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysisJ Acquir Immune Defic Syndr2012591394622067667
- de MendozaCAntaLGarcíaFHIV-1 genotypic drug resistance interpretation rules – 2009 Spanish guidelinesAIDS Rev2009111395119290033
- BrochotAVisPCorbettCGeneralized additive modelling of virologic response to the NNRTIs rilpivirine (RPV, TMC278) and efavirenz (EFV) in treatment-naive HIV-infected patients: pooled week 48 data from ECHO and THRIVE13th European AIDS ConferenceOctober 12–15, 2011Belgrade, Serbia Abstract no PS12/7
- NelsonMBehrensGCohenCSustained efficacy with low and similar rates of virologic failures in second year observed with rilpivirine (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF (FTC/TDF) in treatment-naive, HIV-1 infected adults: pooled 96-week ECHO and THRIVE analysis13th European AIDS Conference (EACS)October 12–15, 2011Belgrade, Serbia Abstract no LBPE7.3/7
- BehrensGRijndersBNelsonMEfficacy and safety outcomes for rilpivirine (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF (FTC/TDF) in treatment-naïve, HIV-1-positive adults with baseline viral load ≤ 100,000 copies/mL-pooled 48-week ECHO and THRIVE analysisAIDS 2012: XIX International AIDS conferenceJuly 22–27, 2012Washington, DC Abstract no TUPE023
- WhiteKVan EygenVVingerhoetsJWeek 96 resistance analysis of the pooled ECHO and THRIVE Truvada subset in treatment-naıïve HIV-infected adults with ≤100,000 c/mL baseline viral load18th Annual Conference of the British HIV AssociationApril 18–20, 2012Birmingham, UK Abstract no P187
- MathiasAMenningMWeiXBioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DF18th International AIDS ConferenceJuly 18–23, 2010Vienna, Austria Abstract no LBPE17
- CohenCJWohlDArribasJSTAR study: single-tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults11th International Congress on Drug Therapy in HIV infectionNovember 11–15, 2012Glasgow, UK Abstract no O425
- FisherMPalellaFTebasPSPIRIT study: switching boosted PI to Rilpivirine In combination with Truvada as an STR adults11th International Congress on Drug Therapy in HIV infectionNovember 11–15, 2012Glasgow, UK Abstract no P285
- MillsACohenCDeJesusEVirologic suppression is maintained in virologically suppressed HIV-1 infected subjects switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) single-tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) STR: week-24 results of GS-11118th Annual Conference of the British HIV Association (BHIVA)April 18–20, 2012Birmingham, UK Abstract no P186
- CohenCJMolinaJMCahnPECHO Study GroupTHRIVE Study GroupEfficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsJ Acquir Immune Defic Syndr201260334222343174
- MillsAAntinoriAClotetBNeurologic and psychiatric safety profile of TMC278 compared with EFV in treatment-naive HIV-1+ patients: ECHO and THRIVE trials at 48 weeks18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27–March 2, 2011Boston, MA Abstract no 420
- RashbaumBGirardPRachlisARilpivirine (RPV, TMC278) tolerability over the first 12 weeks of treatment in the phase 3 ECHO and THRIVE studies51st Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 17–20, 2011Chicago, IL Abstract no H2-805
- VanveggelSBuelensACrauwelsHTMC27825 mg/qd has no effect on corrected QT (QTC) interval in HIV-negative volunteers47th Annual Meeting of the Infectious Diseases Society of AmericaOctober 29–November 1, 2009Philadelphia, PA Abstract no 285
- WohlDDoroanaMOrkinCChange in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with efavirenz: 48-week results from the phase III ECHO trial18th Conference on Retroviruses and Opportunistic Infections;February 27–March 2, 2011Boston, MA Abstract no O1014
- ArribasJAndrade-VillanuevaJBellosNLipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 data from the randomized, double-blind, Phase III ECHO and THRIVE trials18th Conference on Retroviruses and Opportunistic InfectionsFebruary 27–March 2, 2011Boston, MA Abstract no 0304
- CohenCJMolinaJMCassettiIPooled week 96 efficacy, resistance and safety results from the double- blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults6th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionJuly 17–20, 2011Rome, Italy Abstract no TULBPE032
- ParientiJJBangsbergDRVerdonRGardnerEMBetter adherence with once-daily antiretroviral regimens: a meta-analysisClin Infect Dis200948448448819140758
- NachegaJBMugaveroMJZeierMVitóriaMGallantJETreatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costsPatient Prefer Adherence2011535736721845035
- AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Prefer Adherence2010411512520517472
- BaeJWGuyerWGrimmKAlticeFLMedication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and researchAIDS201125327929021239892
- WilligJHAbromsSWestfallAOIncreased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapyAIDS200822151951196018784459
- ColomboGLColangeliVDi BiagioADi MatteoSViscoliCVialePCost-effectiveness analysis of initial HIV treatment under Italian guidelinesClinicoecon Outcomes Res2011319720522163167
- ColomboGLDi MatteoSMaggioloFAntiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of single tablet regimenClinicoecon Outcomes Res20135596823430273
- RizzardiniGRestelliUBonfantiPCost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhileClinicoecon Outcomes Res2012424525222973114
- MaggioloFDi MatteoSMasiniGCost-effectiveness analysis of first line HAART11th International Congress on Drug Therapy in HIV infectionNovember 11–15, 2012Glasgow, UK Abstract no P096
- Lyseng-WilliamsonKAScottLJEmtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infectionClin Drug Investig20123210715722